JP2021074010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021074010A5 JP2021074010A5 JP2021015452A JP2021015452A JP2021074010A5 JP 2021074010 A5 JP2021074010 A5 JP 2021074010A5 JP 2021015452 A JP2021015452 A JP 2021015452A JP 2021015452 A JP2021015452 A JP 2021015452A JP 2021074010 A5 JP2021074010 A5 JP 2021074010A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- thalassemia
- anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 3
- 208000008601 Polycythemia Diseases 0.000 claims 3
- 208000002903 Thalassemia Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 2
- 208000005980 beta thalassemia Diseases 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 1
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims 1
- 208000025499 G6PD deficiency Diseases 0.000 claims 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 101000798696 Homo sapiens Transmembrane protease serine 6 Proteins 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 201000006288 alpha thalassemia Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000006602 delta-Thalassemia Diseases 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 102000018511 hepcidin Human genes 0.000 claims 1
- 229940066919 hepcidin Drugs 0.000 claims 1
- 108060003558 hepcidin Proteins 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 229940126836 transmembrane protease serine 6 synthesis reducer Drugs 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022033166A JP2022104917A (ja) | 2015-04-03 | 2022-03-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142986P | 2015-04-03 | 2015-04-03 | |
| US62/142,986 | 2015-04-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546624A Division JP6833705B2 (ja) | 2015-04-03 | 2016-04-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033166A Division JP2022104917A (ja) | 2015-04-03 | 2022-03-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021074010A JP2021074010A (ja) | 2021-05-20 |
| JP2021074010A5 true JP2021074010A5 (enExample) | 2022-01-06 |
| JP7037681B2 JP7037681B2 (ja) | 2022-03-16 |
Family
ID=57007353
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546624A Active JP6833705B2 (ja) | 2015-04-03 | 2016-04-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
| JP2021015452A Active JP7037681B2 (ja) | 2015-04-03 | 2021-02-03 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
| JP2022033166A Withdrawn JP2022104917A (ja) | 2015-04-03 | 2022-03-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546624A Active JP6833705B2 (ja) | 2015-04-03 | 2016-04-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033166A Withdrawn JP2022104917A (ja) | 2015-04-03 | 2022-03-04 | Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10415038B2 (enExample) |
| EP (1) | EP3277817A4 (enExample) |
| JP (3) | JP6833705B2 (enExample) |
| KR (1) | KR102539587B1 (enExample) |
| CN (1) | CN107429250B (enExample) |
| AU (1) | AU2016244106B2 (enExample) |
| CA (1) | CA2978100C (enExample) |
| HK (1) | HK1249140A1 (enExample) |
| IL (2) | IL253509B2 (enExample) |
| MX (1) | MX2017012426A (enExample) |
| RU (1) | RU2017137410A (enExample) |
| WO (1) | WO2016161429A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| KR102604132B1 (ko) | 2015-12-14 | 2023-11-17 | 콜드스프링하버러보러토리 | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| TWI840345B (zh) * | 2018-03-02 | 2024-05-01 | 美商Ionis製藥公司 | Irf4表現之調節劑 |
| EP3788065B1 (en) | 2018-04-30 | 2025-08-27 | The Children's Hospital Of Philadelphia | Improving anemias by combining agents |
| BR112020022512A2 (pt) | 2018-05-04 | 2021-05-04 | Stoke Therapeutics, Inc. | métodos e composições para tratamento de doença de armazenamento de éster de colesteril |
| EP3598995A1 (en) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
| CN113631709A (zh) * | 2018-12-20 | 2021-11-09 | 普拉克西斯精密药物股份有限公司 | 用于治疗kcnt1相关病症的组合物和方法 |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| JP2023130528A (ja) * | 2020-06-24 | 2023-09-21 | 田辺三菱製薬株式会社 | Ｐｌｐ１発現を調節するための化合物、方法及び医薬組成物 |
| CA3195722A1 (en) | 2020-09-17 | 2022-03-24 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
| AU2022265493A1 (en) | 2021-04-27 | 2023-09-21 | Silence Therapeutics Gmbh | Sirna targeting tmprss6 for the treatment of myeloproliferative disorders |
| WO2022232395A2 (en) * | 2021-04-28 | 2022-11-03 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
| CN115247173B (zh) * | 2021-11-11 | 2025-11-11 | 南京启真基因工程有限公司 | 构建tmprss6基因突变的缺铁性贫血猪核移植供体细胞的基因编辑系统及其应用 |
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| WO2024060649A1 (zh) * | 2022-09-29 | 2024-03-28 | 广州必贝特医药股份有限公司 | 用于抑制TMPRSS6基因表达的siRNA或其盐、药物及其应用 |
| CN117136236B (zh) * | 2022-09-29 | 2024-03-15 | 广州必贝特医药股份有限公司 | 用于抑制TMPRSS6基因表达的siRNA或其盐、药物及其应用 |
| AU2024244929A1 (en) | 2023-03-27 | 2025-09-11 | New York Blood Center, Inc. | Compounds and compositions for use in stem cell transplantation |
| TW202527968A (zh) * | 2024-01-08 | 2025-07-16 | 大陸商上海舶望製藥有限公司 | 用於抑制跨膜絲氨酸蛋白酶6（tmprss6）表達的組合物和方法 |
| WO2025206092A1 (ja) * | 2024-03-27 | 2025-10-02 | 田辺三菱製薬株式会社 | Ｍｙｏｒｅｇｕｌｉｎ発現を調節するための化合物及び医薬組成物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| PT1178999E (pt) | 1999-05-04 | 2007-06-26 | Santaris Pharma As | Análogos de l-ribo-lna |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6906182B2 (en) | 2000-12-01 | 2005-06-14 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP1560840B1 (en) | 2002-11-05 | 2015-05-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| US7888497B2 (en) | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | Ｎ−ｏ結合性架橋構造型新規人工核酸 |
| WO2005023835A2 (en) | 2003-09-09 | 2005-03-17 | Irm Llc | Modulators of transmembrane protease serine 6 |
| WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
| US8178503B2 (en) | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| WO2008024858A2 (en) | 2006-08-22 | 2008-02-28 | University Of Virginia Patent Foundation | Methods and compounds regulating the erythroid response to iron deficiency |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| EP3705125B1 (en) | 2007-12-04 | 2023-07-05 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US8530640B2 (en) | 2008-02-07 | 2013-09-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| EP2294181A4 (en) | 2008-05-22 | 2013-04-24 | Isis Pharmaceuticals Inc | MODULATION OF SMRT EXPRESSION |
| EP2331141B1 (en) * | 2008-08-25 | 2016-01-06 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| CN106146591B (zh) | 2010-01-08 | 2020-07-31 | Ionis制药公司 | 血管生成素样3表达的调节 |
| CN113736782B (zh) * | 2011-03-29 | 2024-07-16 | 阿尔尼拉姆医药品有限公司 | 用于抑制tmprss6基因表达的组合物和方法 |
| CN108410868A (zh) * | 2011-09-20 | 2018-08-17 | Ionis制药公司 | Gcgr表达的反义调节 |
| HRP20191883T1 (hr) * | 2011-11-07 | 2019-12-27 | Ionis Pharmaceuticals, Inc. | Modulacija ekspresije tmprss6 |
| JP2016528873A (ja) | 2012-05-16 | 2016-09-23 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| WO2014190157A1 (en) * | 2013-05-22 | 2014-11-27 | Alnylam Pharmaceuticals, Inc. | Tmprss6 compositions and methods of use thereof |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| EP3262181B1 (en) | 2015-02-23 | 2024-04-10 | Ionis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
-
2016
- 2016-04-04 JP JP2017546624A patent/JP6833705B2/ja active Active
- 2016-04-04 KR KR1020177030957A patent/KR102539587B1/ko active Active
- 2016-04-04 WO PCT/US2016/025883 patent/WO2016161429A1/en not_active Ceased
- 2016-04-04 MX MX2017012426A patent/MX2017012426A/es unknown
- 2016-04-04 US US15/562,843 patent/US10415038B2/en active Active
- 2016-04-04 RU RU2017137410A patent/RU2017137410A/ru not_active Application Discontinuation
- 2016-04-04 HK HK18108870.8A patent/HK1249140A1/zh unknown
- 2016-04-04 CN CN201680015815.4A patent/CN107429250B/zh active Active
- 2016-04-04 CA CA2978100A patent/CA2978100C/en active Active
- 2016-04-04 AU AU2016244106A patent/AU2016244106B2/en active Active
- 2016-04-04 EP EP16774409.3A patent/EP3277817A4/en active Pending
-
2017
- 2017-07-16 IL IL253509A patent/IL253509B2/en unknown
-
2019
- 2019-08-01 US US16/528,925 patent/US20200190522A1/en not_active Abandoned
-
2021
- 2021-02-03 JP JP2021015452A patent/JP7037681B2/ja active Active
- 2021-09-24 US US17/484,386 patent/US20220259600A1/en not_active Abandoned
- 2021-09-26 IL IL286669A patent/IL286669A/en unknown
-
2022
- 2022-03-04 JP JP2022033166A patent/JP2022104917A/ja not_active Withdrawn
-
2023
- 2023-07-25 US US18/358,591 patent/US20240026364A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021074010A5 (enExample) | ||
| JP2018511307A5 (enExample) | ||
| TWI767937B (zh) | 外核苷酸酶抑制劑及其使用方法 | |
| US9605018B2 (en) | Substituted nucleotide analogs | |
| US20230002437A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| JP2625257B2 (ja) | 主鎖修飾されたオリゴヌクレオチド類似体 | |
| RU2017137410A (ru) | Соединения и способы модулирования экспрессии tmprss6 | |
| JP2018530325A5 (enExample) | ||
| JP2002504558A (ja) | ２’−フルオロヌクレオシド | |
| US9676797B2 (en) | Anti-viral compounds | |
| TW201524990A (zh) | 經取代之核苷、核苷酸及其類似物 | |
| TW201808981A (zh) | 用於肝臟疾病之ｄ-胺基酸化合物 | |
| US20220363709A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| JPH07508000A (ja) | １，２，３−トリアゾール及びイミダゾール化合物並びにそれらの抗腫瘍用途 | |
| WO2014194848A1 (zh) | 多靶点型乌苯美司前药衍生物及其制备方法和用途 | |
| US11248016B2 (en) | Glycolipids and pharmaceutical compositions thereof for use in therapy | |
| JPWO2022032288A5 (enExample) | ||
| WO2024073399A2 (en) | Dna-affibody-drug nanostructures for inhibiting triple negative breast cancer growth and metastasis | |
| WO1994022886A9 (en) | Heteroatomic oligonucleoside linkages | |
| JP2879973B2 (ja) | ヘテロ原子によるオリゴヌクレオシド連結 | |
| WO2010065685A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia | |
| US20100291234A1 (en) | Compositions and methods for treating inflammatory arthritis | |
| JP7766375B2 (ja) | 変形されたｒｔ－ｌｅｔ７を有効成分として含む肝癌の予防または治療用組成物 | |
| JPWO2023278607A5 (enExample) | ||
| WO2022250072A1 (ja) | 心疾患治療薬 |